GENOMAS, INC.

Basic Information

67 JEFFERSON ST
HARTFORD, CT, 06106

Company Profile

n/a

Additional Details

Field Value
DUNS: 147969526
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 5


  1. System for DNA-Guided Optimization and Personalization of Statin Therapy

    Amount: $1,250,027.00

    DESCRIPTION (provided by applicant): Currently 30 million Americans with elevated cholesterol receive statin therapy, making statins the most prescribed drug class in the U.S. Statin Induction and Neu ...

    SBIR Phase II 2011 Department of Health and Human Services
  2. MRI DNA Biomarkers for Neuropsychiatric Disease

    Amount: $1,349,950.00

    DESCRIPTION (provided by applicant): Schizophrenia (SZ) is a severely debilitating mental illnesses. It is highly heritable, with concordance rates of 50-80% in monozygotic twins and substantial famil ...

    SBIR Phase II 2009 Department of Health and Human Services
  3. DNA Diagnostic System for Statin Safety and Efficacy

    Amount: $143,338.00

    DESCRIPTION (provided by applicant): Statins are the most prescribed drugs in the world. Their efficacy in primary and secondary prevention of cardiovascular disease as well as beneficial pleiotrophic ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. DNA Diagnostic System for Statin Safety and Efficacy

    Amount: $1,008,599.00

    DESCRIPTION (provided by applicant): Statins are the most prescribed drugs in the world. Their efficacy in primary and secondary prevention of cardiovascular disease as well as beneficial pleiotrophic ...

    SBIR Phase II 2008 Department of Health and Human Services
  5. DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

    Amount: $449,182.00

    DESCRIPTION (provided by applicant): Atypical antipsychotic drugs (AAPs) are indicated in the treatment for schizophrenia, bipolar disorder, psychotic depression and other psychiatric disorders. Their ...

    SBIR Phase II 2007 Department of Health and Human Services
  6. Physiogenomic Arrays for Clinical Neuropsychiatry

    Amount: $400,000.00

    DESCRIPTION (provided by applicant): Neuropsychiatric and neurodegenerative disorders such as schizophrenia, Alzheimer's disease, and depression are genetically complex diseases with multiple contribu ...

    SBIR Phase I 2005 Department of Health and Human Services
  7. Gene Markers: Antipsychotic-Induced Metabolic Syndrome

    Amount: $107,000.00

    DESCRIPTION (PROVIDED BY APPLICANT): This Phase I SBIR Program will develop genetic diagnostic products to improve the safety of atypical antipsychotics (e.g. olanzapine) for treating psychiatric diso ...

    SBIR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government